Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TP-1287 in Advanced Solid Tumors
NCT03604783Phase 1Terminated
- Sponsor
- Sumitomo Pharma America
- Start
- Dec 2018
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tp-1287 in solid tumor (advanced stage), sarcoma, Ewing sarcoma and 2 more, sponsored by Sumitomo Pharma America. Primary endpoints: Incidence of Dose-Limiting Toxicities at 21 days, Maximum Tolerated Dose at 20 months and 2 more. Started Dec 2018; status: terminated.
02
Drugs
tp-1287
03
Conditions
solid tumor (advanced stage)sarcomaEwing sarcomadedifferentiated liposarcoma (DDL)synovial sarcoma (SS)
Beyond the preview
Go deeper on NCT03604783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03604783.